Safety and Tolerability in Early AOM Use The safety profile of anti-obesity medications (AOMs) requires careful consideration when implementing early intervention strategies for GLP-1 non-responders
This work was supported by institutional funds from the Feinstein Institutes for Medical Research, and in part through a Northwell Health Cancer Institute Pilot Award for Mentoring in Cancer Research
It is one of the world's largest drug manufacturers, with a strong presence in diabetes care
The popular brand is developed by skincare specialists with more than 30 years of experience in research and development
At higher doses (300+ mcg), some users experience increased hunger, mild headaches, or joint discomfort from rapid tissue growth
By telling them about any worries or side effects, you help them give you the best care for your health needs